13:11 ETLonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancersprnewswire·Jun 15 at 12:13 PMO6Z0.00%
Lonza: Q1 Performance In Line With Expectations; Confirms 2026 Outlooknasdaq·May 8 at 01:00 AMO6Z0.00%LZAGY+1.93%
Lonza says big pharma might delay outsourcing decisions amid US investmentsMSN·May 8 at 12:45 AMLZAGY+1.93%O6Z0.00%
Assessing Lonza Group’s Valuation As FDA AI Collaboration Puts Its Drug Development Capabilities In FocusSimplywall·Apr 28 at 01:02 PMO6Z0.00%LZAGY+1.93%
13:57 ETGlobal CMO/CDMO Market Set for Steady Growth as Biologics Outsourcing and Specialized Manufacturing Drive Demand | Future Market Insights (FMI)prnewswire·Apr 14 at 12:59 PMLZAGY+1.93%O6Z0.00%
Lonza Group (SWX:LONN) Is Up 5.8% After 25% Dividend Hike And Board Refresh - Has The Bull Case Changed?Simplywall·Apr 1 at 12:52 PMO6Z0.00%LZAGY+1.93%
Biotin Ingredients Market Outlook 2026-2036: Global Market to Reach USD 10.61 Billion by 2036 at 10.90% CAGR | FMI ReportMorningStar·Mar 18 at 01:56 AMPBE-0.66%SY1
Kepler Capital Reaffirms Their Buy Rating on Lonza Group Ltd (LONN)Tip Ranks·Mar 10 at 08:48 PMO6Z0.00%
